Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 161

Similar articles for PubMed (Select 22448928)

1.

Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database.

Lambert T, Emmerson B, Hustig H, Resseler S, Jacobs A, Butcher B; e-STAR Research Group.

BMC Psychiatry. 2012 Mar 26;12:25. doi: 10.1186/1471-244X-12-25.

2.

Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.

Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A.

Curr Med Res Opin. 2010 Mar;26(3):501-9. doi: 10.1185/03007990903488670.

PMID:
20014981
3.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
4.

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, Lam A, Villalobos Vega JC, Cuéllar JA, de Castro FJ, Quintero CM, Martíin JF, Domínguez P, Ojeda JL, Cortés SS, Cala FI, Marín CG, Castro LM, Duaso MA, Albarracín JR, Vergara GN, Benítez AF, Cleries FM, Pérez-Brian JM, Aragón AB, Navarro JC, Biedma JA, de Pedro RB, González JF, López ME, Moreno HD, López JA, Rodríguez EO, de Hoyos CM, Sacristán MP, Martín MD, Ballesteros EM, Rodríguez PA, Menéndez LF, Rivas RS, del Pino Cuadrado P, Lauffer JC, Solano JJ, Martínez JM, Solano FG, Rodríguez PG, Rodríguez JA, Cano TR, Fortacin MD, Lobeiras JM, Sampedro JM, Bravo AP, Pellicer AF, López MD, Liste JF, Fernández MR, Losada AC, Mendez RV, Romero SA, Blanco JJ, Bonaselt IT, Mahia MC, del Valle EF, Yañez PQ, Camarasa MG, Alonso JA, Mendez GF, Feliz FD, Lamela MA, Piñero MV, Alvarado PF, Gómez IL, Martín PF, Gómez JL, López AG, Jiménez AR, Nafs AE, Barquero NC, Ortiz RF, Noguera JL, Carrasco PR, Muñoz JM, Palma MM, Hortelano CM, Bonome LS, Sevilla JS, Juan JM, Ramos JM, Muñoz JL, Guisasola JE, Vazquez LS, Guerras FC, Nebot FJ, Fernández FJ, Nicolau AL, Subirats RC, Kidias MM, Navarro VF, García BF, del Rosal FM, de Vicente Muñoz T, Ballester JA, Lieb PM, Martel AD, Bea ER, Joaquim IG, Enjuanes FB, Piñol MB, Carbonell EF, Muñoz RM, Giribets CA, Sans LA, Blanco AS, Felipe MA, Muñoz PG, Villanueva AP, Arroyo MB, Borri RC, Fallada SM, Merola MC, Rodon EP, Palmes JR, Martínez EP, Catala JM, Coca AS, Ferrandiz FP, Paya EF, Caballero GI, Bonet AF, Figueras JF, Pagador PM, Garibo MM, Camo VP, Carrillo CS, Valero CP, Rebollo FJ, García Campayo J, Sala Ayma JM, Roig MM, de Uña Mateos MA, Bertolin RG, García AM, Mazo FJ, Velasco JL, Pérez LS, Casado CJ, Barba JJ, Diaz MC, Rubio JP, Mandoli AS, Herrero AU, Martínez AR, Serrano PS, Rodríguez EN, Montesinos JS, Macia JF, Mateos Marcos AM, Soto JV, Dumont MV, Pagan JP, Martínez VB, Santiuste de Pablos M, Delgado CE, Quiles MD, López FJ, Navarro PP, Torres AM, Ingles FJ, Arias-Camison JM, Manzano JC, Peña RV, Guitarte GP, Fontecilla HB, Romero JB, Gil RS, Lozano JM, Adanez LD, Zarranz Herrera-Oria I, Jiménez JP, Vaz FC, García OS, Anton CC, Casula RR, Hernandez MC, Escabias FT, Torresano JR, Pérez-Villamil AH, Estevez L, Figuero MA, Muñoz de Morales A, Calvin JL, Criado MD, Rodríguez VM, Ambrosolio EB, Madera PM, Alfaro GP, Vidal MM, Valtuille AG, Ruiz O, Cabornero GL, Echevarria Martínez de Bujo M, Mallen MJ, Puigros JS, Martorell AL, Forteza AC, Arrebola ER, Rodríguez de la Torre M, Saiz CG, Bardolet I Casas C, Linde ER, De Arce Cordon R, Molina EM, Carazo FJ, Romero JJ, Cano DV, Dorado MS, Velazquez SC, Sánchez AJ, Leon SO, Sánchez KP, Benitez MH, Zugarramurai AI, Contreras MA, De la Varga González M, Marín PB, Robina FG, García MS, Pérez FJ, Bros PC, Gómez AC, de Dios Molina Martín J, Perera JL, Averbach MC, Perera JL, Palancares EG, Gallego de Dios MT, Rojo CF, Iglesias SS, Merino MI, Mestre NP, Urdaniz AP, Sánchez JM, Seco RG, Muñoz JF, Agut MM, Lozano ML, Herguedas FM, Pena AT, García JV, Martínez AV, Sanz Granado OS, Fernández MA, Canseco JM, López PA, Martín MA, Barrio JA, Ubago JG, Bennassar MR, Díez JM, Fleta JL, Fortes FP, López CA, Medina O, Alvarez DF, Roca JM, Valladolid GR, Tavera JA, García-Castrillon Sales JA, Llordes IB, Melgarejo CA, Cañas de la Paz F, Callol VV, García MB, García JB, Leal FJ, Corrales EC, Iglesias ES, Gómez MA, Serrano GG, Chillarón EG, Aguado FJ, Castillo JJ, González AG, Vázquez JG, Peralvarez MB, Diaz MR, Mesa MY, Artiles FJ, Chao MA, Mesa MY, del Rosario Santana P, Escudero MA, Berenguer MM, Llacer JM, Berna JA, Ortiz JB, Pardell LT, Hernández-Alvarez de Sotomayor C, Méndez MR, Garate RC, Múgica BD, González MC, Domingo JP, Navarro CS, Vera GS, Cuquerella MA, Monzo JL, Boada PC, Pérez MF, Parrado EC, Sánchez JJ, Fernández JC; e-STAR Spanish Study Group.

Eur Psychiatry. 2009 Jun;24(5):287-96. doi: 10.1016/j.eurpsy.2008.12.002. Epub 2009 Feb 4.

PMID:
19195847
5.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
6.

Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.

Taylor DM, Young CL, Mace S, Patel MX.

J Clin Psychiatry. 2004 Aug;65(8):1076-83.

PMID:
15323592
7.

Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry.

Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS; e-STAR Study Group.

Curr Med Res Opin. 2009 Sep;25(9):2197-206. doi: 10.1185/03007990903149306.

PMID:
19604073
8.

A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.

Lee NY, Kim SH, Cho SJ, Chung YC, Jung IK, Kim CY, Kim DH, Lee DG, Lee YH, Lim WJ, Na YS, Shin SE, Woo JM, Yoon JS, Yoon BH, Ahn YM, Kim YS.

Int Clin Psychopharmacol. 2014 Sep;29(5):279-87. doi: 10.1097/YIC.0000000000000030.

PMID:
24583566
9.
10.

Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome.

Taylor DM, Young C, Patel MX.

Int J Neuropsychopharmacol. 2006 Dec;9(6):685-94. Epub 2005 Nov 23.

PMID:
16939663
11.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
12.

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies.

Möller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E; StoRMi Study Group.

Int Clin Psychopharmacol. 2005 May;20(3):121-30.

PMID:
15812261
13.

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.

Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turner MS, Medori R, Gaebel W.

J Psychopharmacol. 2005 Sep;19(5 Suppl):5-14.

PMID:
16144781
15.

Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.

Parellada E, Kouniakis F, Siurkute A, Schreiner A, Don L.

Int Clin Psychopharmacol. 2010 May;25(3):149-54. doi: 10.1097/YIC.0b013e328336c93f.

PMID:
20305567
16.

[Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].

Raignoux C, Dusouchet T, Bret P, Queuille E, Biscay ML, Caron J, Bret MC.

Encephale. 2007 Dec;33(6):973-81. doi: 10.1016/j.encep.2006.07.003. Epub 2007 Sep 4. French.

PMID:
18789790
17.

Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.

Barrio P, Batalla A, Castellví P, Hidalgo D, García M, Ortiz A, Grande I, Pons A, Parellada E.

Int Clin Psychopharmacol. 2013 Jul;28(4):164-70. doi: 10.1097/YIC.0b013e3283611cc3.

PMID:
23587986
18.

Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.

Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K.

Hum Psychopharmacol. 2010 Jan;25(1):37-46. doi: 10.1002/hup.1085.

PMID:
20041474
19.

Prognostic indicators for early discontinuation of risperidone long-acting injection.

Patel MX, Young C, Samele C, Taylor DM, David AS.

Int Clin Psychopharmacol. 2004 Jul;19(4):233-9.

PMID:
15201571
20.

Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.

Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG; Risperidone Long-Acting Trial Investigators (R-LAI).

Hum Psychopharmacol. 2009 Oct;24(7):574-83. doi: 10.1002/hup.1067.

PMID:
19790173
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk